|
TAFENOQUINE
 INN TAFENOQUINE
|
cas 106635-80-7 |
CLASS ANTIPARASITIC ANTIMALARIAL 8-AMINOQUINOLINE ACTIVE AGAINST ALL THE STAGES OF PLASMODIUM SPECIES INHIBITS HEMATIN POLYMERIZATION AND INDUCES APOPTOTIC LIKE DEATH OF THE PARASITE |
|
ATC code
P01BA07 |
PK parameters Tmax 14 HOUR VD 2470 LITER Cl 4.2 LITER / HOUR PPB 99.5 PERCENT t1/2 396 HOUR
|
Target - |
DrugCentral Unknown |
Download SDF file |
1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- Formula: C24H28F3N3O3 Calculated chemical properties: MW 463.49 NB_atoms 33 XLogP 5.91 PSA 75.09 NB_HD 3 NB_HA 6 fsp3 0.38 Lipinski(0=no;1=yes) 0 |
FDA NDA 210795 (pdf not found) INN (TAFENOQUINE SUCCINATE) KRINTAFEL (GLAXOSMITHKLINE) APPROVAL= AP YEAR= 2018 NEWMOLECULARENTITY NDA 210607 (pdf not found) INN (TAFENOQUINE SUCCINATE) ARAKODA (60 DEGREES PHARMS) APPROVAL= AP YEAR= 2018 |
Other links: PubChem ChemicalProbes U.S. repository of Clinical Trials VigiAccess SIDER side effects ChemSynthesis Patent@SureChEMBL |